| Scott Anthony Mckee, MD | |
|
55 Whitcher St Ne, Suite 350, Marietta, GA 30060-1155 | |
| (770) 424-6893 | |
| (770) 528-9938 |
| Full Name | Scott Anthony Mckee |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 24 Years |
| Location | 55 Whitcher St Ne, Marietta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700903465 | NPI | - | NPPES |
| 655344968J | Medicaid | GA | |
| 655344968K | Medicaid | GA | |
| 655344968M | Medicaid | GA | |
| 655344968L | Medicaid | GA | |
| 655344968N | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 058908 (Georgia) | Secondary |
| 207RI0011X | Internal Medicine - Interventional Cardiology | 58908 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellstar Kennestone Hospital | Marietta, GA | Hospital |
| Wellstar Douglas Hospital | Douglasville, GA | Hospital |
| Wellstar Cobb Hospital | Austell, GA | Hospital |
| Wellstar Paulding Hospital | Hiram, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellstar Medical Group, Llc | 6709065402 | 1839 |
News Archive
StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.
The development and first use of a high-density SNP array for the malaria vector mosquito have established 400,000 genetic markers capable of revealing new insights into how the insect adapts to outsmart insecticides and other preventive measures, according to findings published in the current edition of the journal Science.
A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.
Federal government labs in Atlanta were temporarily shut after it was discovered they had improperly sent potentially deadly pathogens, including anthrax, botulism and virulent bird flue virus, to other labs.
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
› Verified 2 days ago
| Entity Name | Kennestone Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649248626 PECOS PAC ID: 3870490816 Enrollment ID: O20031217000515 |
News Archive
StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.
The development and first use of a high-density SNP array for the malaria vector mosquito have established 400,000 genetic markers capable of revealing new insights into how the insect adapts to outsmart insecticides and other preventive measures, according to findings published in the current edition of the journal Science.
A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.
Federal government labs in Atlanta were temporarily shut after it was discovered they had improperly sent potentially deadly pathogens, including anthrax, botulism and virulent bird flue virus, to other labs.
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
› Verified 2 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.
The development and first use of a high-density SNP array for the malaria vector mosquito have established 400,000 genetic markers capable of revealing new insights into how the insect adapts to outsmart insecticides and other preventive measures, according to findings published in the current edition of the journal Science.
A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.
Federal government labs in Atlanta were temporarily shut after it was discovered they had improperly sent potentially deadly pathogens, including anthrax, botulism and virulent bird flue virus, to other labs.
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott Anthony Mckee, MD 55 Whitcher St Ne, Suite 350, Marietta, GA 30060-1155 Ph: (770) 424-6893 | Scott Anthony Mckee, MD 55 Whitcher St Ne, Suite 350, Marietta, GA 30060-1155 Ph: (770) 424-6893 |
News Archive
StemCells, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.
The development and first use of a high-density SNP array for the malaria vector mosquito have established 400,000 genetic markers capable of revealing new insights into how the insect adapts to outsmart insecticides and other preventive measures, according to findings published in the current edition of the journal Science.
A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.
Federal government labs in Atlanta were temporarily shut after it was discovered they had improperly sent potentially deadly pathogens, including anthrax, botulism and virulent bird flue virus, to other labs.
BioTrends Research Group released topline findings from LaunchTrends®: ACTEMRA, Wave 1 today, highlighting the market uptake of the product at one month post launch. Actemra (tocilizumab), marketed by Roche-Genentech, is a new IL-6 inhibitor with monthly dosing by IV infusion. The study results are based on an on-line survey completed by 77 rheumatologists in late February.
› Verified 2 days ago
Anu Kurl, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 400 Tower Rd Ne Ste 160, Marietta, GA 30060 Phone: 770-420-1690 Fax: 770-420-1661 | |
Dr. Sharon M Odell, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 54 Tower Rd Ne, Marietta, GA 30060 Phone: 770-427-4682 Fax: 770-499-8562 | |
Dr. Helga Annalina Bahr, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 580 Atlanta Country Club Drive, Marietta, GA 30068 Phone: 770-988-8554 | |
Dr. Kaynessa Celena Providence, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 54 Tower Rd Ne, Marietta, GA 30060 Phone: 770-427-4682 Fax: 770-499-8562 | |
Dr. Ryan V Cantwell, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 Kennestone Hospital Blvd, Suite 201, Marietta, GA 30060 Phone: 770-427-2457 Fax: 770-427-2706 | |
Dr. Joanne Zhiwen Zhu, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 677 Church St Ne # 111, Marietta, GA 30060 Phone: 770-793-7750 | |
Asif A Saberi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 55 Whitcher St Ne, Suite 160, Marietta, GA 30060 Phone: 770-422-1372 Fax: 770-423-9651 |